- May 10, 2016
- Comments: 0
- Posted by: admin
Society Interventional Radiology 2016.
Bariatric arterial embolization (BAE) was associated with sustained weight loss and significant appetite suppression in a small pilot study of morbidly obese individuals.
BAE could offer obese individuals a minimally invasive alternative to surgical weight loss approaches, according to Dr. Clifford Weiss, director of interventional radiology research at Johns Hopkins University School of Medicine in Baltimore.
He presented results of the pilot trial at the Society of Interventional Radiology annual meeting in Vancouver, British Columbia.
BAE targets the gastric fundus, which produces the powerful hunger hormone ghrelin. A trained interventional radiologist uses image guidance and catheters to access the specific blood vessels leading to the gastric fundus through a small incision in the skin at either the groin or wrist.Through this small incision microscopic beads are injected to decrease blood flow to fundus of the stomach.This leads to suppression of hunger signals, leading to reduced appetite and weight loss.
Participants included seven morbidly obese but otherwise healthy adults with a body mass index between 40 and 60 kg/m2 (mean BMI, 43.8 kg/m2). Their mean age was 37 years.
All participants were evaluated by multidisciplinary team to implement lifestyle and diet changes before and after the procedure. At 1, 3 and 6 months after BAE, researchers tracked the subjects weight loss, ghrelin levels, hunger and satiety ratings, quality of life, blood pressure, and adverse events.
In the first month after BAE, participants had an average excess-weight loss of 5.9%. Encouragingly,after six months, excess-weight loss increased to an average of 13.3%.In these first seven patients, there were no “major adverse events, so the treatment was found to be safe.It was also noted that ghrelin levels “trended down, and quality-of-life scores improved.” And all patients lost weight loss and reported being less hungry after the procedure.